利爾化學(002258.SZ)上修業績預告:一季度淨利潤預增10.73%-19.04%
格隆匯4月10日丨利爾化學(002258.SZ)發佈2020年1-3月業績預告修正公告,此前在《2019年年度報告摘要》中披露,預計2020年1-3月歸屬於上市公司股東的淨利潤同比變動幅度為-30.79%至1.04%,即預計2020年1-3月歸屬於上市公司股東的淨利潤區間為5000萬元至7300萬元。
修正後,預計2020年度第一季度歸屬於上市公司股東的淨利潤8000萬元-8600萬元,同比增長10.73%-19.04%。
自2020年3月以來,公司部分產品的銷售價格和銷售數量較原有預計出現差異,以及人民幣匯率變動也超出原有預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.